Q-omics provides the consensus-scored KLF10 profile across patient tissues and cancer cell-line models. KLF10 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, KLF10 is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, KLF10 RNA expression shows 19,233 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LUSC, KICH, and ACC as cancer lineages where KLF10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLF10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLF10 survival associations across molecular data types. KLF10 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLF10 RNA expression–survival associations across cancer types. High KLF10 expression shows unfavorable associations in LUSC, PAAD, LGG, HNSC and CESC, but favorable associations in KIRC. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for KLF10 RNA expression.
This table summarizes KLF10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in KICH for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for KLF10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLF10 shows lower tumor expression in KICH, THCA, LUAD, LUSC, UCEC and BRCA. The KICH box plot shows higher KLF10 RNA expression in normal versus tumor tissue (log2 FC = −2.138, t-test p < 0.001).
This table shows molecular features associated with KLF10 in patient tissues and cancer cell lines. In patient samples, KLF10 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, KLF10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in CNS and BONE.
